These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 24314245)

  • 1. [Invasive lobular carcinoma of basal-like subtype of breast: a clinicopathologic analysis].
    Zhang LY; Gao LX; Liu G; Yang GZ; Cheng J; Ding HY
    Zhonghua Bing Li Xue Za Zhi; 2013 Sep; 42(9):599-603. PubMed ID: 24314245
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A subset of breast cancer predisposes to brain metastasis.
    Shao MM; Liu J; Vong JS; Niu Y; Germin B; Tang P; Chan AW; Lui PC; Law BK; Tan PH; Tse GM
    Med Mol Morphol; 2011 Mar; 44(1):15-20. PubMed ID: 21424932
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Heterogeneity of luminal breast cancer characterised by immunohistochemical expression of basal markers.
    Sung H; Garcia-Closas M; Chang-Claude J; Blows FM; Ali HR; Figueroa J; Nevanlinna H; Fagerholm R; Heikkilä P; Blomqvist C; Giles GG; Milne RL; Southey MC; McLean C; Mannermaa A; Kosma VM; Kataja V; Sironen R; Couch FJ; Olson JE; Hallberg E; Olswold C; Cox A; Cross SS; Kraft P; Tamimi RM; Eliassen AH; Schmidt MK; Bolla MK; Wang Q; Easton D; Howat WJ; Coulson P; Pharoah PD; Sherman ME; Yang XR
    Br J Cancer; 2016 Feb; 114(3):298-304. PubMed ID: 26679376
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinicopathlogic and immunohistochemical characteristics of triple negative invasive lobular carcinoma.
    Koo JS; Jung W
    Yonsei Med J; 2011 Jan; 52(1):89-97. PubMed ID: 21155040
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Specific sites of metastases in invasive lobular carcinoma: a retrospective cohort study of metastatic breast cancer.
    Inoue M; Nakagomi H; Nakada H; Furuya K; Ikegame K; Watanabe H; Omata M; Oyama T
    Breast Cancer; 2017 Sep; 24(5):667-672. PubMed ID: 28108967
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparisons of p53, KI67 and BRCA1 expressions in patients with different molecular subtypes of breast cancer and their relationships with pathology and prognosis.
    Li Y; Zhang X; Qiu J; Pang T; Huang L; Zeng Q
    J BUON; 2019; 24(6):2361-2368. PubMed ID: 31983107
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunohistochemical features of multifocal and multicentric lobular breast carcinoma.
    Ilić IR; Petrović A; Živković VV; Randjelović PJ; Stojanović NM; Radulović NS; Randjelović D; Ilić RS
    Adv Med Sci; 2017 Mar; 62(1):78-82. PubMed ID: 28189947
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The expression of cytokeratin 5/6 in invasive lobular carcinoma of the breast: evidence of a basal-like subset?
    Fadare O; Wang SA; Hileeto D
    Hum Pathol; 2008 Mar; 39(3):331-6. PubMed ID: 18261623
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fragile histidine triad protein, WW domain-containing oxidoreductase protein Wwox, and activator protein 2gamma expression levels correlate with basal phenotype in breast cancer.
    Guler G; Huebner K; Himmetoglu C; Jimenez RE; Costinean S; Volinia S; Pilarski RT; Hayran M; Shapiro CL
    Cancer; 2009 Feb; 115(4):899-908. PubMed ID: 19130459
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunohistochemical analysis of ER, PR, HER-2, CK 5/6, p63 and EGFR antigen expression in medullary breast cancer.
    Matkovic B; Juretic A; Separovic V; Novosel I; Separovic R; Gamulin M; Kruslin B
    Tumori; 2008; 94(6):838-44. PubMed ID: 19267102
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differences in Response and Surgical Management with Neoadjuvant Chemotherapy in Invasive Lobular Versus Ductal Breast Cancer.
    Truin W; Vugts G; Roumen RM; Maaskant-Braat AJ; Nieuwenhuijzen GA; van der Heiden-van der Loo M; Tjan-Heijnen VC; Voogd AC
    Ann Surg Oncol; 2016 Jan; 23(1):51-7. PubMed ID: 25980321
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Apocrine carcinoma as triple-negative breast cancer: novel definition of apocrine-type carcinoma as estrogen/progesterone receptor-negative and androgen receptor-positive invasive ductal carcinoma.
    Tsutsumi Y
    Jpn J Clin Oncol; 2012 May; 42(5):375-86. PubMed ID: 22450930
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synchronous squamous cell carcinoma of the breast and invasive lobular carcinoma.
    Sentani K; Tashiro T; Oue N; Yasui W
    APMIS; 2007 Dec; 115(12):1422-5. PubMed ID: 18184414
    [No Abstract]   [Full Text] [Related]  

  • 14. Discordance in ER, PR, HER2, and Ki-67 Expression Between Primary and Recurrent/Metastatic Lesions in Patients with Primary Early Stage Breast Cancer and the Clinical Significance: Retrospective Analysis of 75 Cases.
    Peng L; Zhang Z; Zhao D; Zhao J; Mao F; Sun Q
    Pathol Oncol Res; 2021; 27():599894. PubMed ID: 34257555
    [No Abstract]   [Full Text] [Related]  

  • 15. Invasive pleomorphic lobular carcinoma, negative for ER, PR and Her/2neu--a case report.
    Manucha V; Khilko N; Reilly K; Zhang X
    Int J Clin Exp Pathol; 2011 Jan; 4(2):200-5. PubMed ID: 21326816
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic Significance of Progesterone Receptor Expression in Estrogen-Receptor Positive, HER2-Negative, Node-Negative Invasive Breast Cancer With a Low Ki-67 Labeling Index.
    Ono M; Tsuda H; Yoshida M; Shimizu C; Kinoshita T; Tamura K
    Clin Breast Cancer; 2017 Feb; 17(1):41-47. PubMed ID: 27477822
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Tubulolobular carcinoma of breast: a clinicopathologic study of 8 cases].
    Shi J; Liang ZY; Meng ZL; Luo YF; Cao JL; Yang CM; Liu TH
    Zhonghua Bing Li Xue Za Zhi; 2012 Oct; 41(10):681-5. PubMed ID: 23302310
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Associations between the standardized uptake value of (18)F-FDG PET/CT and the prognostic factors of invasive lobular carcinoma: in comparison with invasive ductal carcinoma.
    Jung NY; Kim SH; Choi BB; Kim SH; Sung MS
    World J Surg Oncol; 2015 Mar; 13():113. PubMed ID: 25889560
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of ER/PR and HER2 statuses in primary and paired liver metastatic sites of breast carcinoma in patients with or without treatment.
    Liu J; Deng H; Jia W; Zeng Y; Rao N; Li S; Jin L; Wu J; Song E; Su F
    J Cancer Res Clin Oncol; 2012 May; 138(5):837-42. PubMed ID: 22290394
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of Neoadjuvant Chemotherapy on Breast Cancer Subtype: Does Subtype Change and, if so, How? : IHC Profile and Neoadjuvant Chemotherapy.
    De La Cruz LM; Harhay MO; Zhang P; Ugras S
    Ann Surg Oncol; 2018 Nov; 25(12):3535-3540. PubMed ID: 29981025
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.